How to Value Your Invention

Every inventor eventually faces the same question: what is this worth? The answer matters whether you are deciding how much to invest in patent prosecution, negotiating a licensing deal, selling a patent, pitching to investors, or simply deciding whether to continue pursuing a technology. Getting the answer wrong in either direction is costly — undervaluing leaves money on the table, overvaluing wastes resources chasing deals that will never close.

Invention valuation is not a precise science. It combines financial analysis, market assessment, legal evaluation, and commercial judgment. No formula produces a definitive number. But a structured approach — applied honestly — gives you a defensible, realistic range that can anchor negotiations and guide decisions.

Why Valuation Is Difficult

Before diving into methods, it helps to understand why invention valuation is inherently imprecise.

Patents are contingent assets. A patent application is not yet a patent. Even a granted patent may be narrowed or invalidated. The value of an invention's IP protection depends on whether it will be granted, in what form, and whether it will survive a validity challenge.

Commercial value is uncertain. An invention's value depends on whether it can be commercialised, at what price, at what volume, against what competition. All of these are unknowns at the time most valuations are conducted.

Comparable transactions are opaque. Most patent transactions are confidential. The public data on licensing rates and patent sale prices is a fraction of total market activity and may not be representative.

Value depends on who is doing the valuing. The same patent may be worth very little to a company with no presence in the relevant market and enormously valuable to a company that is already infringing it. Value is not intrinsic to the patent — it depends on the relationship between the patent and the specific counterparty.

With these caveats in mind, here are the frameworks that practitioners use.

Framework 1: The Cost Approach

What it measures: What has the invention cost to create and protect?

How it works: Add up all costs associated with the invention — research and development expenditure, prototype costs, patent filing and prosecution fees, maintenance fees paid to date, and any licensing fees or royalties already paid to access necessary background IP.

Formula: Invention value = R&D costs + IP protection costs + commercialisation costs incurred

Example:

• Research and development: USD $45,000
• Prototype development: USD $15,000
• Patent prosecution (US + PCT + China): USD $35,000
• Total cost basis: USD $95,000

When to use it: The cost approach establishes a floor — a rational seller will not accept less than their sunk costs unless there are compelling reasons to exit. It is also useful in early-stage negotiations as a minimum anchor.

Limitations: The cost approach almost never captures the true commercial value of an invention. A patent that cost $20,000 to obtain may protect a technology worth millions. Conversely, a patent that cost $50,000 to obtain may cover technology no one wants to buy. Cost is a floor, not a ceiling, and often not even an accurate floor for commercially significant inventions.

Framework 2: The Market Approach

What it measures: What have comparable patents or inventions sold or licensed for?

How it works: Identify transactions involving patents or inventions that are comparable in technology area, claim breadth, remaining term, and commercial application. Use those transaction prices or royalty rates as benchmarks for your own valuation.

Sources of comparable data:

Patent transaction databases:

• ktMINE (ktmine.com) — one of the largest databases of disclosed patent licensing transactions, searchable by technology category, CPC class, and industry
• Royalty Range (royaltyrange.com) — royalty rate benchmarks across industries, useful for establishing appropriate royalty rates in licensing negotiations
• IAM Market (iam-market.com) — patent sale transactions and asking prices
• Derwent Innovation / PatSnap — commercial patent analytics with transaction data

Published royalty rate surveys: Industry associations and consulting firms publish periodic surveys of royalty rates by technology sector. These provide useful ranges:

These ranges are starting points, not targets. A specific transaction's royalty rate depends on exclusivity, patent strength, remaining term, the parties' respective negotiating positions, and what share of the licensee's profits is attributable to the patent.

The 25% Rule: A widely cited (if contested) heuristic holds that a reasonable royalty is approximately 25% of the licensee's expected profit from the use of the patented technology. Courts in the US have questioned this rule's universal application, but it remains a useful starting point for structuring initial negotiating positions.

When to use it: The market approach is most useful when comparable transactions are available and when the goal is to arrive at a negotiating benchmark rather than a theoretical value. In practice, it works best in combination with the income approach.

Limitations: Most licensing transactions are confidential. Available data skews toward disclosed transactions, which may not reflect typical market terms. Technology areas, claim scope, and commercial contexts vary enormously — "comparable" is always a judgment call.

Framework 3: The Income Approach

What it measures: The present value of the future income stream the patent will generate.

How it works: Estimate the royalty income (or other economic benefit) the invention will generate over its remaining commercial life, then discount that income stream to present value using an appropriate discount rate that reflects the risk of the investment.

The basic formula:

Invention Value = Σ [Annual Income × (1 – tax rate)] ÷ (1 + discount rate)^n

Where:

• Annual income = projected royalty revenue or economic benefit per year
• Tax rate = applicable tax on IP income in the relevant jurisdiction
• Discount rate = required rate of return reflecting the risk of the IP asset
• n = year number (from 1 to remaining patent life)

Worked example (simplified):

Assume:

• US utility patent with 12 years of remaining life
• Projected royalty revenue: USD $500,000 per year (based on 3% royalty on $16.7M addressable sales)
• Tax rate on IP income: 25%
• Discount rate: 20% (reflecting significant commercial uncertainty)

Year 1 present value: $500,000 × (1 – 0.25) ÷ (1 + 0.20)^1 = $312,500 Year 2 present value: $500,000 × 0.75 ÷ (1.20)^2 = $260,417 ...and so on for each remaining year.

Sum of all discounted cash flows over 12 years ≈ USD $1.4M (at these assumptions).

This is a simplified illustration. In practice, projections include ramp-up periods, competitive obsolescence, probability of enforcement success, and validity risk.

Key inputs and how to estimate them:

Addressable revenue: The total sales of products that incorporate or would benefit from the patented technology, in all licensed markets. This is the royalty base. Market research, industry reports, and comparable product sales data inform this estimate.

Royalty rate: The share of the royalty base paid to the licensor. Use the market approach benchmarks above as a starting point, adjusted for exclusivity and patent strength.

Remaining patent life: The number of years remaining in each jurisdiction, accounting for maintenance fee obligations.

Commercial obsolescence: Technology often becomes commercially obsolete before the patent expires. A 20-year patent on a specific electronic component technology may have only 8–10 years of meaningful commercial value before it is superseded. Apply a declining income profile if obsolescence is likely.

Discount rate: Reflects the risk of the IP asset. A patent on a pharmaceutical compound in clinical trials carries enormous uncertainty and warrants a high discount rate (30%–50%). A patent on an established mechanical technology with identified licensees may warrant a lower rate (15%–25%). General guidance:

• Very early stage, no commercial validation: 40%–60%
• Working prototype, no licensee: 25%–40%
• Patent pending or granted, licensee interested: 20%–30%
• Patent granted, licensing agreement in place: 15%–20%

Probability of enforcement: Not all patents can be enforced successfully. A patent on a technology that is easy to design around, that faces serious prior art risk, or where infringement is difficult to detect, is worth less than a patent on a broad, defensible, easily monitored technology. Apply a probability factor to reflect this.

When to use it: The income approach is the most rigorous method and the one most commonly used in significant licensing transactions, corporate acquisitions, and litigation damages calculations. It is also the most demanding in terms of inputs.

Framework 4: The Relief-from-Royalty Method

A variant of the income approach commonly used in accounting and corporate finance contexts. The logic: a company that owns a patent avoids paying royalties it would otherwise have to pay to use the technology. The value of the patent is the present value of those avoided royalty payments.

Formula: Patent Value = Revenue attributable to the patent × Royalty rate × (1 – tax rate), discounted to present value

This approach is widely used in purchase price allocation for acquisitions and in fair value accounting under IFRS and US GAAP. It is less appropriate for licensing negotiations (where it may understate the licensor's position) but useful for corporate financial reporting contexts.

Adjusting for Non-Financial Value Factors

Raw financial projections must be adjusted for qualitative factors that affect the reliability and sustainability of the income stream:

Patent strength and claim breadth: A patent with broad independent claims that are difficult to design around is worth significantly more than one with narrow claims easily circumvented. Review the claims with a patent attorney and get an honest assessment of their defensive value.

Validity risk: Does the patent face known prior art challenges? Has it survived an opposition or IPR proceeding? A patent that has been challenged and survived is significantly stronger than one that has never been tested.

Freedom to operate: Does the invention infringe any third-party patents? An invention that requires a licence from a third party to practice may have substantially reduced commercial value.

Remaining term: A patent with 18 years of remaining life is substantially more valuable than one with 3 years, all else being equal. Calculate remaining life in each jurisdiction separately — a portfolio of patents with staggered expiry dates is more valuable than a single patent.

Multi-jurisdiction coverage: A patent granted only in the US has lower value than one granted in the US, EU, China, Japan, and South Korea — particularly if the technology is manufactured or sold globally. Coverage in manufacturing jurisdictions (especially China) and major consumer markets multiplies value.

Related IP assets: Is there a patent family — continuations, divisionals, related applications — that extends protection? Is the invention also protected by trade secrets, trademarks, or copyrights that complement the patent? Broader IP protection reduces the risk that competitors can freely use the technology after the patent expires.

Exclusivity of access: Is this a sole inventor holding the patent, or are there co-inventors or co-owners whose consent is required for licensing? A patent encumbered by co-ownership complications or existing licences is worth less than an unencumbered sole-ownership patent.

The Risk-Adjusted Score Card

For inventors who want a quick, structured way to assess relative value without full financial modelling, the following scorecard provides a useful orientation:

Scoring guide:

• 5 = Exceptional (broad claims, 18+ years, 5+ major jurisdictions, confirmed infringement, large growing market, survived IPR, large family)
• 3 = Average (moderate claims, 10 years, 2–3 jurisdictions, likely infringement, medium market, no known prior art risk, 1–2 continuations)
• 1 = Weak (narrow claims, under 5 years, single jurisdiction, no infringement detectable, small market, prior art concerns, no family)

Weighted score interpretation:

• 4.0–5.0: High-value asset, potentially worth $1M+ in the right licensing context
• 2.5–3.9: Moderate-value asset, may support licensing at $50K–$500K range
• 1.0–2.4: Low-value asset, likely worth less than prosecution and maintenance costs

This scorecard is a heuristic, not a valuation. Use it to prioritise which inventions to invest in and which to abandon.

Valuation in Different Contexts

The same invention may be valued differently depending on the purpose of the valuation:

Licensing negotiation: The licensor wants to maximise the present value of the royalty stream; the licensee wants to minimise it. The income approach anchors the negotiation. Each party will have their own assumptions about royalty rate, addressable market, and risk — the negotiation bridges those gaps.

Patent sale: The seller wants to recover at least their costs and ideally the income approach value. The buyer will discount for their own risk assessment and transaction costs. Sale prices for individual patents frequently fall below what the income approach would suggest because buyers apply significant discounts for uncertainty.

Investment pitch: Investors assess patents as part of the overall business case. A patent portfolio does not directly attract investment — the business opportunity it enables does. Valuation in this context focuses on how the IP protection creates and defends a commercial moat.

Balance sheet / financial reporting: Under IFRS (IAS 38) and US GAAP (ASC 350), internally generated patents are typically not recognised on the balance sheet. Acquired patents are recognised at fair value (purchase price allocation) and amortised. The relief-from-royalty method is most commonly used for financial reporting valuations.

Litigation damages: Courts assessing reasonable royalty damages look for what a hypothetical willing licensor and willing licensee would have agreed to at the time infringement began — the "hypothetical negotiation." This is heavily income-approach based, informed by the Georgia-Pacific factors in US courts and equivalent frameworks in other jurisdictions.

Divorce, estate, and insolvency proceedings: Courts in many jurisdictions need to value IP assets for division or liquidation purposes. Formal appraisal by a qualified IP valuation professional is typically required.

Professional Valuation Services

For significant transactions — a major licensing deal, a corporate acquisition, litigation damages, or balance sheet fair value — a formal valuation by a qualified professional is advisable. Look for:

Chartered IP valuers: The Licensing Executives Society (LES), the International Valuation Standards Council (IVSC), and national valuers' associations (RICS in the UK; AVA or ASA in the US; HKVS in Hong Kong; SAVI in Singapore) accredit IP valuation professionals.

Specialist firms: Firms including Kroll, Duff & Phelps (now Kroll), Ocean Tomo, Pluritas, and Anaqua provide IP valuation services for licensing, M&A, and litigation contexts.

Cost: Professional IP valuations range from USD $5,000 for a basic preliminary assessment to $50,000–$200,000+ for a full defensible valuation in a litigation or M&A context.

Tax Considerations in Invention Valuation

The value of an invention is not just its gross commercial potential — it is the after-tax economic benefit. Tax frameworks for IP income vary significantly by jurisdiction and should be factored into any serious valuation:

IP Box regimes: Many jurisdictions offer reduced tax rates on income derived from qualifying IP assets. Netherlands (9% Innovation Box), UK (10% Patent Box), Luxembourg (80% IP income exemption), Ireland (6.25% Knowledge Development Box), Belgium (4.44% effective rate), Singapore (IP Development Incentive) — these regimes can dramatically increase the after-tax value of an IP asset for a correctly structured holder.

Withholding taxes on royalties: Cross-border royalty payments typically attract withholding tax in the source country. Tax treaty networks reduce (sometimes eliminate) withholding tax between treaty partners. The structure of a licensing arrangement significantly affects the net royalty income to the licensor.

Capital gains on patent sale: The tax treatment of patent sale proceeds varies — capital gains (often more favourable) in some jurisdictions, ordinary income in others. See: How to Sell Your Patent

Transfer pricing: For multinational enterprises, intercompany IP licensing transactions must be priced at arm's length under OECD guidelines. Incorrect transfer pricing creates tax authority challenge risk.

A Worked Valuation Example

Here is a realistic valuation exercise for a hypothetical invention — a patented quick-connect coupling mechanism for industrial hose systems, with a granted US patent and a pending European application.

Cost approach (floor): R&D and prototyping: $30,000. Patent prosecution (US granted + EPO pending): $40,000. Total sunk costs: $70,000. This is the minimum a rational seller should accept.

Market approach (benchmark): Research on comparable licensing transactions in industrial fluid handling components shows royalty rates of 2–5% of net sales for non-exclusive licenses. The median is 3.5%.

Income approach (ceiling): The addressable market is industrial hose fittings in the US — approximately $400M annually. The inventor estimates their coupling could capture 2% of this market if adopted by a major manufacturer — $8M in annual sales to the licensee. At a 3.5% royalty rate, that is $280,000 per year in royalties. Over a 15-year remaining patent term, discounted at 15% (reflecting commercialisation risk), the net present value is approximately $1.6M.

But this is the optimistic scenario. Apply adjustments: 70% probability the licensee achieves projected sales volumes (adjusted NPV: $1.12M). 80% probability the European patent grants with commercially useful claims (reduces the portfolio value slightly). 90% probability the US patent survives a validity challenge (it is granted and has been examined).

Resulting valuation range: $70,000 (floor) to $1.12M (risk-adjusted income). A reasonable licensing negotiation anchors around $400,000–$600,000 in total deal value — a lump-sum upfront plus running royalties.

What this exercise teaches: Valuation is not about finding the "right number." It is about constructing a defensible range that tells you what to accept, what to reject, and what to negotiate. An inventor who walks into a licensing discussion with this analysis has infinitely more leverage than one who says "I was hoping for a million dollars."

The Hard Truth About Invention Value

Most inventions are worth less than their inventors believe. This is not cynicism — it is arithmetic.

The value of an invention is not determined by how clever it is, how much time you spent on it, or how strongly you feel about it. It is determined by how much money someone else can make with it, minus what they could make without it. If a manufacturer can achieve 80% of the same result with a slightly different design that does not infringe your patent, your patent's incremental value is the remaining 20% — not 100%.

The inventors who extract the most value from their patents are those who understand this clearly. They do not negotiate based on what they feel the invention is worth. They negotiate based on the financial impact the invention creates for the licensee — and they can articulate that impact in the licensee's own terms.

If you cannot calculate the licensee's cost savings, revenue increase, or competitive advantage from using your patent — in numbers — you are not ready to negotiate.

Sources

1. WIPO - IP Valuation — International resources and methodologies for valuing intellectual property assets
2. USPTO - Patent Assignment — US patent transaction records and assignment data useful for market comparables
3. European Patent Office — European patent information and technology landscape data
4. Lens.org — Open patent and scholarly search platform for patent family analysis and citation data